A McNulty, Y Li, U Radtke, J Kaldor, R Rohrsheim, D A Cooper, B Donovan
{"title":"Herpes zoster and the stage and prognosis of HIV-1 infection.","authors":"A McNulty, Y Li, U Radtke, J Kaldor, R Rohrsheim, D A Cooper, B Donovan","doi":"10.1136/sti.73.6.467","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To examine the incidence of herpes zoster in HIV-1 infection. To assess the prognostic significance of the occurrence of herpes zoster and progression to AIDS or death</p><p><strong>Design and methods: </strong>146 homosexually active men with known times of HIV-1 seroconversion were identified through the Sydney AIDS Prospective Study and the clinic records of a private medical practice with large caseload of HIV infected homosexual men. Medical records were reviewed for a history of herpes zoster, CD4+ lymphocyte counts, and HIV-1 disease status. Cox's proportional hazards model was used to determine whether herpes zoster predicted progression to AIDS or death.</p><p><strong>Results: </strong>After a mean follow up of 54 months, 30 men (20%) had an episode of herpes zoster and three of these men had one recurrence. The overall incidence of herpes zoster was 44.4 episodes per 1000 person years (95% CI 30.0-63.5). Herpes zoster was not found to be a marker of deteriorating immune functions as measured by CD4+ lymphocyte counts. CD4+ counts did not differ significantly between those with and without zoster at 1 year (551 v 572.10(6)/1, p = 0.79), 2 years (451 v 557, p = 0.11), and 3 years (424 v 481, p = 0.50) following HIV-1 seroconversion. There was no statistically significant difference in progression to AIDS (RR = 1.89, 95% CI 0.80-4.46, p = 0.15) or death (RR = 0.90, 95% CI 0.31-2.65, p = 0.85) from HIV-1 sero-conversion in those who did and those who did not develop herpes zoster.</p><p><strong>Conclusion: </strong>The incidence of herpes zoster was consistent with the findings of other studies. There was no association between the occurrence of herpes zoster and progression of HIV-1 disease.</p>","PeriodicalId":12621,"journal":{"name":"Genitourinary Medicine","volume":"73 6","pages":"467-70"},"PeriodicalIF":0.0000,"publicationDate":"1997-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1136/sti.73.6.467","citationCount":"29","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genitourinary Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/sti.73.6.467","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 29
Abstract
Objectives: To examine the incidence of herpes zoster in HIV-1 infection. To assess the prognostic significance of the occurrence of herpes zoster and progression to AIDS or death
Design and methods: 146 homosexually active men with known times of HIV-1 seroconversion were identified through the Sydney AIDS Prospective Study and the clinic records of a private medical practice with large caseload of HIV infected homosexual men. Medical records were reviewed for a history of herpes zoster, CD4+ lymphocyte counts, and HIV-1 disease status. Cox's proportional hazards model was used to determine whether herpes zoster predicted progression to AIDS or death.
Results: After a mean follow up of 54 months, 30 men (20%) had an episode of herpes zoster and three of these men had one recurrence. The overall incidence of herpes zoster was 44.4 episodes per 1000 person years (95% CI 30.0-63.5). Herpes zoster was not found to be a marker of deteriorating immune functions as measured by CD4+ lymphocyte counts. CD4+ counts did not differ significantly between those with and without zoster at 1 year (551 v 572.10(6)/1, p = 0.79), 2 years (451 v 557, p = 0.11), and 3 years (424 v 481, p = 0.50) following HIV-1 seroconversion. There was no statistically significant difference in progression to AIDS (RR = 1.89, 95% CI 0.80-4.46, p = 0.15) or death (RR = 0.90, 95% CI 0.31-2.65, p = 0.85) from HIV-1 sero-conversion in those who did and those who did not develop herpes zoster.
Conclusion: The incidence of herpes zoster was consistent with the findings of other studies. There was no association between the occurrence of herpes zoster and progression of HIV-1 disease.
目的:探讨带状疱疹在HIV-1感染中的发病率。为评估带状疱疹的发生和艾滋病进展或死亡的预后意义,设计和方法:通过悉尼艾滋病前瞻性研究和一家私人医疗机构的大量HIV感染男同性恋者的临床记录,确定了146名已知HIV-1血清转化次数的同性恋活跃男性。回顾了患者的带状疱疹病史、CD4+淋巴细胞计数和HIV-1疾病状态。Cox比例风险模型用于确定带状疱疹是否预示着发展为艾滋病或死亡。结果:平均随访54个月后,30名男性(20%)出现带状疱疹发作,其中3名复发。带状疱疹的总发病率为每1000人年44.4次(95% CI 30.0-63.5)。通过CD4+淋巴细胞计数,带状疱疹并不是免疫功能恶化的标志。在HIV-1血清转化后1年(551 v 572.10(6)/1, p = 0.79)、2年(451 v 557, p = 0.11)和3年(424 v 481, p = 0.50),带状疱疹患者和非带状疱疹患者的CD4+计数无显著差异。在发生带状疱疹和未发生带状疱疹的HIV-1血清转化患者中,进展为艾滋病(RR = 1.89, 95% CI 0.80-4.46, p = 0.15)或死亡(RR = 0.90, 95% CI 0.31-2.65, p = 0.85)的差异无统计学意义。结论:带状疱疹的发病率与其他研究结果一致。带状疱疹的发生与HIV-1疾病的进展之间没有关联。